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Background: There is no single model available to predict the long term survival for patients starting renal
replacement therapy (RRT). The available models either predict survival on dialysis until transplantation, survival on
the transplant waiting list, or survival after transplantation. The aim of this study was to develop a model that
includes dialysis survival and survival after an eventual transplantation.
Methods: From the Dutch renal replacement registry, patients of 16 years of age or older were included if they
started RRT between 1995 and 2005, still underwent RRT at baseline (90 days after the start of RRT) and were not
registered at a non-renal organ transplant waiting list (N = 13868). A prediction model of 10-year patient survival
after baseline was developed through multivariate Cox regression analysis, in one half of the research group. Age at
start, sex, primary renal disease (PRD) and therapy at baseline were included as possible predictors. A sensitivity
analysis has been performed to determine whether listing on the transplant waiting list should be added. The
predictive performance of the model was internally validated. Calibration and discrimination were computed in the
other half of the research group. Another sensitivity analysis was to assess whether the outcomes differed if the
model was developed and tested in two geographical regions, which were less similar than the original
development and validation group. No external validation has been performed.
Results: Survival probabilities were influenced by age, sex, PRD and therapy at baseline (p < 0.001). The calibration
and discrimination both showed very reasonable results for the prediction model (C-index = 0.720 and calibration
slope for the prognostic index = 1.025, for the 10 year survival). Adding registration on the waiting list for renal
transplantation as a predictor did not improve the discriminative power of the model and was therefore not
included in the model.
Conclusions: With the presented prediction model, it is possible to give a reasonably accurate estimation on the
survival chances of patients who start with RRT, using a limited set of easily available data.Background
In the Netherlands, in recent years approximately 2000
new patients with end stage renal disease (ESRD) start
chronic renal replacement therapy (RRT) every year.
Even though the kidney replacement programs already
exist for more than forty years, it is still not possible to
predict the long term survival chances for all RRT* Correspondence: a.hemke@transplantatiestichting.nl
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reproduction in any medium, provided the orpatients during the initial phase of their therapy, using
one single model.
Existing prediction models look at dialysis survival
until transplantation [1], patient survival on the trans-
plant waiting list [2-5], patient survival after transplant-
ation [6,7], or focus on a specific patient group in which
differences in treatment modality are less likely [8].
However, none of the available predication models focus
on survival for the complete group of incident RRT
patients, taking into account survival after dialysis
combined with survival after a possible transplantation.
As it is not clear at therapy initiation whether a patientLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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be transplanted, the available models cannot be used to
predict survival for all patients at the start of RRT.
To be able to give a survival prognosis in an early
stage of the renal replacement therapy to every patient,
we need a model that predicts patient survival chances
based on characteristics that are known at that point in
time. In the present study, based on national data from
the renal replacement registry, a prediction model on
the survival prognosis for incident RRT patients in the
Netherlands was developed and validated.
The objective of this study is to develop a prediction
model that could be used by physicians to inform pa-
tients about their survival chances at the start of RRT,
based on a few very easily obtainable variables.
Methods
In the Dutch renal replacement registry, all ESRD patients
with chronic renal replacement therapy, meaning kidney
function replacement for at least 4 weeks consecutively,
are registered. These patients have given written informed
consent for submission of their data to the national registry.
The Renine data control committee, which manages the
registry, has approved the use of the data in the registry for
this particular research. For this study, the baseline situation
for the prognosis was the therapy at 90 days after theTable 1 Demographics of patients, N = 13868
Patients starting a renal replacement therapy in 1995–2005, ≥16 years
age, with a registered primary renal disease and peritoneal dialysis,
hemodialysis or a functioning kidney transplant at 90 days after the st
Sex Male
Age group 16-44 year
45-64 year
65-74 year
75 year or older
Primary renal disease Diabetes
Renal vascular disease
Glomerulonephritis
Cystic kidney disease
Other diseases*
Unknown**
Start year renal replacement 1995 – 2000
2001 – 2005
Therapy at baseline Transplantation
Hemodialysis
Peritoneal dialysis
*The group “other diseases” consists of the subcategories interstitial nephritis (9.4%
diseases (5.4%) and other primary renal diseases (5.1%).
**The primary kidney disease “unknown” is included as a separate category in the p
possible to determine the original disease. This is a specific recognisable category ostart of renal replacement therapy, as the intention to
treat. We chose 90 days as the baseline of our study to
ensure enough time to switch from a temporary needed
therapy to the intended treatment and to exclude patients
who only have to undergo renal replacement therapy for a
short period of time. The primary renal disease (PRD) is
coded in the registry according to the ERA-EDTA coding
system and for our analysis grouped into 6 categories.
PRD “unknown” is a specific category, as the nephrologist
was not able to define the original kidney disease, so these
are probably shrunken kidneys. If the PRD is missing, it
could be any disease, and therefore it is different from
PRD unknown. The included patients are Dutch residents
of 16 years of age or older at the start of RRT, who started
RRT in the period of 1995–2005, who still underwent a
RRT at baseline, and who were not registered at the
waiting list for another organ transplant than kidney
(N = 14783). Selected patient and treatment characteris-
tics were sex, age at start of RRT, PRD and therapy at
90 days, and the outcome was patient survival. Exclusion
criteria were not registered PRD (N= 518), recovered
kidney function (N = 322), lost to follow-up (N = 48), un-
known kidney transplant type (N = 20), transplant failure
before baseline (N = 3) or home hemodialysis as baseline
therapy (N = 4). The final study group consisted of 13868
patients (Table 1). The events from 90 days after theof
art
Total
N = 13868
%
Development group
N = 6934
%
Validation group
N = 6934
%
P-value
%
60.2 61.1 59.4 0.04
17.1 17.6 16.7 0.47
36.9 36.9 36.9
28.4 28.4 28.4
17.6 17.2 17.9
16.7 16.6 16.8 0.71
25.3 25.2 25.3
12.3 12.5 12.1
9.0 8.8 9.2
21.4 21.8 21.0
15.2 14.9 15.5
50.3 50.9 49.6 0.15
49.7 49.1 50.4
3.0 2.8 3.2 0.32
65.7 65.5 65.9
31.3 31.7 31
), other congenital and hereditary kidney diseases (1.5%), other multisystem
rognosis, as these are probably shrunken kidneys, whereby it was no longer
f patients, and therefore this is a separate diagnosis in the prognostic formula.
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were analyzed; the follow-up period was maximized at
10 years. For the development and validation of the
prediction model, the study group was randomly divided
in a development (N = 6934) and a validation group
(N = 6934).
Statistical analysis
The analysis was performed using SPSS 19 and STATA.
Survival was analyzed with Kaplan Meier and log rank
tests. Linearity of the influence of patient age on survival
was assessed with Kaplan Meier stratified by different
age groups. The proportionality assumption has been
tested by visual inspection of the Schoenfeld residuals
plot [9]. For the survival prognosis from 90 days after
the start of RRT, multivariate Cox regression analysis
was performed in the development group. The formula
for the survival probability at time t, S(t), is S(t) = exp
(−H(t)). Here H(t) is the cumulative hazard that is calcu-
lated from the baseline hazard (H0) as H(t) = H0(t)*exp
(prognostic index). The prognostic index (PI) is the sum
of the parameter estimates from the Cox regression
multiplied by the patient characteristics for a specific
patient. To validate the prediction model, the predictive
performance was assessed by computing the calibration
and the discrimination of the prediction model for the
3, 5 and 10 year survival in the validation group [10,11].
Calibration refers to the agreement between observed
outcomes and predicted survival probabilities. This was
measured by a) the calibration in the large, which indi-
cates the extent that predictions are systematically too
low or too high, b) a calibration plot for ten deciles
according to the predicted survival, which is plotted
against the observed survival, which ideally should be
on the 45-degree line, and c) the calibration slope, whichTable 2 Cox regression model for patient mortality 90 days a
Patient characteristics Parameter estim
Primary renal disease
Glomerulonephritis Reference
Cystic kidney disease −0.280
Renal vascular disease 0.331
Diabetes 0.767
Other diseases 0.407
Unknown 0.296
Therapy at 90 days
Hemodialysis Reference
Peritoneal dialysis −0.131
Kidney transplantation −1.634
Male sex 0.067
Age (per year) 0.054
*The sum of (the product of) parameter estimates gives the value of the prognosticshould be 1. The discrimination is the ability of the model
to distinguish subjects with different outcomes. This was
measured by the concordance (or C-) index. A C-index of
0.5 indicates the model has no discriminative power, while
a model with a C-index of 1.0 has a perfect discriminative
power. As a sensitivity analysis we assessed the conse-
quences of our choice not to include information about
registration on the waiting list as one of the predictors in
the model and the choice for random (instead of geo-
graphical) development and validation group stratification.
Results
The overall 10-year survival of patients on RRT at baseline
was 34%. From the total cohort (N = 13868) 8418 patients
died within 10 years (60.7%). The number of censored
cases was 5450 (39.3%). The mean follow-up time was
5.6 years, the median was 5 years, the minimum was 0.25
and the maximum was 10 years. A prediction model of
10-year patient survival after baseline (90 days after the
start of RRT) was developed through multivariate Cox
regression analysis (with age, sex, PRD, and therapy at
baseline as possible predictors). Based on the visual in-
spection of the Schoenfeld residual plots the proportional-
ity assumption has not been rejected. Age had a linear
relationship with survival. The model was developed in
the development group and validated in the validation
group. In the development group the number of patients
at risk at 1, 3, 5 and 10 year were: 6934, 5190, 3879 and
1223. In Table 1 the development and validation group
were compared and found to be not different except for a
small variation in sex distribution. In Table 2 the Cox re-
gression model is presented with the baseline hazards for
the referent patient group (H0) in Table 3. To illustrate
how these results can be used to compute a survival
probability, consider the following example: a 50 year oldfter start of renal replacement therapy
ate* Hazard ratio 95% confidence interval P-value
<0.001
0.756 0.639-0.894 0.001
1.392 1.232-1.573 <0.001
2.154 1.899-2.444 <0.001
1.502 1.324-1.705 <0.001
1.345 1.178-1.535 <0.001
<0.001
0.877 0.817-0.943 <0.001
0.195 0.117-0.325 <0.001
1.070 1.005-1.139 0.04
1.055 1.052-1.058 <0.001
index of a patient.
Table 3 Baseline hazards for the referent patient group
Period Baseline hazard
1 year 0.0030365610
2 year 0.0062357605
3 year 0.0099612016
4 year 0.0137250602
5 year 0.0171945227
6 year 0.0210066776
7 year 0.0244553143
8 year 0.0277822094
9 year 0.0310576721
10 year 0.0333077563
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toneal dialysis has a prognostic index (PI) of ((age*0.054=)
50*0.054=)2.7) + ((male=)0.067) + ((diabetes=)0.767 + ((peri-
toneal dialysis=)-0.131) = 3.40. Then, the 1-year survival for
this patient is: exp(−(0.0030*exp(3.40))) = exp(−0.09) = 91%.
The 5-year survival for this patient is: exp(−(0.0171*exp
(3.40))) = exp(−0.51) = 60%. The 10-year survival for this
patient is: exp(−(0.0333*exp(3.40))) = exp(−1.0) = 37%.
The model can be used in a simple Excel sheet to draw
an individual survival prediction curve.
To assess the predictive performance of the model, the
calibration and discrimination were computed in the
validation group. The calibration in the large, or overall
calibration, was good with a 50.4% predicted versus
49.5% observed 5-year survival and 32.9% predicted
versus 34.4% observed 10-year survival.
Based on the prognostic index, ten deciles of patients
were distinguished and the observed probability for 3, 5
and 10-year survival was plotted against the predicted
probability in each risk stratum, constituting the calibra-
tion plot (Figure 1). The calibration slope, which ideally
is 1.0, was assessed by a Cox regression analysis using
the prognostic index as the only variable, and had an
outcome of 0.948, 0.990 and 1.025 for the 3, 5 and 10 years
survival respectively. The discriminative power of the pre-
diction model was assessed with the concordance index
and the resulting outcome of the C-index was 0.707 (95%
CI: 0.698-0.717), 0.716 (95% CI: 0.708-0.724) and 0.720
(95% CI: 0.712-0.728) for the 3, 5 and 10 years survival
respectively.
To show robustness of our model, we also performed
sensitivity analyses.
As a first sensitivity analysis the model has been ex-
tended with the registration on the kidney waiting list at
90 days, combined with the therapy at 90 days and pre-
sented together in the model as the status at 90 days.
This model had a similar validity to our current model
with a discrimination of 0.724 and a calibration in thelarge equal, and a calibration by deciles almost equal, to
that of the current model.
As the development group and validation group were
very similar, we also assessed the influence of dividing
the research cohort into two geographical regions, based
on the ZIP-codes of the patients’ addresses. The two
resulting comparable sized regions differed from each
other in age-distribution, PRD-distribution, starting
period, therapy at 90 days and transplantation rate. One
of these regions also differed from the development
group on all mentioned items; the other only differed in
PRD-distribution. Two sensitivity analyses have been
performed. The first was the development of a model in
one region and validating the outcome in the other region.
Parameter estimates of this alternative model did not
differ substantially from our original (and final) model.
This model had a similar validity to our final model
with a discrimination of 0.711 and a calibration almost
equal to that of the final model. The final model was
also validated in the two separate regions. The model
performed well in both regions, with a similar discrimin-
ation (C = 0.71) and calibration slopes of the prognostic
index of 0.982 and 1.040 respectively (data not shown).
Discussion
A prediction model was developed to estimate survival
probabilities at 90 days based on a basic set of patient
characteristics (age at start of RRT, sex and PRD) and the
RRT therapy at 90 days. The main strength of the current
prediction model is that it is based on the complete cohort
of Dutch patients in 1995–2005. The predictive perform-
ance of the model is adequate, as demonstrated by validity
tests on calibration and discrimination of this model,
which could thus be used to inform patients about their
survival prognosis at baseline.
The model uses treatment information at 90 days after
the start of RRT, as the intention to treat. There is a
clear difference in survival between patients who are on
dialysis or who are being transplanted in an early stage.
From previous studies we know that a better survival for
kidney transplantation can be related to both advantages
of the therapy as well as the better condition of the patient
[2,12]. There is also a survival difference between patients
starting on hemodialysis and peritoneal dialysis, which is
also known from literature on this topic. Research has
shown that patients starting on hemodialysis have more
co-morbidities than patients starting on peritoneal dialysis
[13-15]. In the prognostic formula the therapy modality
therefore is included as one of the indicators of patient
condition, as no other clinical information is available in
the complete Dutch patient cohort. Like the ERA-EDTA,
the Dutch renal replacement registry only collects a few
parameters on all patients. Further research should estab-
lish whether the treatment at 90 days, in combination with
Figure 1 Calibration plot prediction model: observed versus predicted 3, 5 and 10 year survival.
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indicating the patient’s condition.
Registration on the kidney transplant waiting list at
90 days was not included as one of the predictors. Other
studies have shown the survival benefit of patients regis-
tered at the waiting list, compared to dialysis patients
not listed for transplantation [12,13,16], suggesting that
this predictor is related to patient condition. For that
reason we performed a sensitivity analysis to test the
possible additional value of this predictor. The additional
predictive performance, however, was negligible. Possibly
this could indicate that there is an overlapping risk
profile between dialysis patients listed and not listed for
transplantation as has been shown by an American study
[17], where they found that many ESRD patients viable
for transplantation were not listed while higher risk
patients had been listed rapidly. The comparable per-
formance of the prediction models with and without
registration on 90 days suggests that the chance to be
in a better general condition and/or to be transplanted
is not only reflected in registration on the waiting list,
but is also covered by the other predictors (age at start,
PRD and therapy at 90 days). Another reason not to in-
clude registration on the kidney transplant waiting list
as a predictor in our model is the fact that the time point
of registration is very arbitrary in the Netherlands. There
was a very large variation in registration time in Dutch
population, and many patients were registered on the
waiting list for kidney transplantation after the period of
90 days, which was our baseline for inclusion. It is not very
likely that there is a difference in condition between
patients that are registered at 90 days or, for instance, at
91 days after the start of RRT.
Some potential limitations of this study should also be
noted.
First, the moderate discriminative power of the predic-
tion model (C-index of 0.720) shows further improvement
possibilities. In this study the age, PRD, and therapy at
90 day are considered to be substitutes for more accurate
clinical indicators on the condition of patients. Adding
clinical patient characteristics, like GFR, proteinuria,
and (historical) co-morbidities, would probably improve
the individual prediction. An English study showed that
the addition of comorbid condition data and laboratory
data could indeed lead to improvement of the predictive
power of the prognostic model from 0.69 to 0.75 [1].
On the other hand the additional effect may be limited,
as age and PRD are highly correlated with comorbidity,
as has also be shown by a European study [18] and a
single centre study in the US [19]. It is therefore desir-
able to study for the Dutch situation whether clinical
data correlate with data already used in this model and
whether they can improve the discriminative power of
the prediction model.Another limitation of the study is that the model is
only internally validated in the validation group, and the
model has not been externally validated in an external
cohort. It would be desirable to test the model in an-
other patient group. This could be a patient cohort from
another country or another period. The generalizability
of the model to another country, however, is doubtful, as
countries differ in dialysis and transplantation possibil-
ities. This should be subject for further research. The
fact that our model focuses on long term survival, makes
external validation in a more recent cohort difficult.
Regular evaluation of the model is needed as treatments
improve in time and RRT-population, treatment possi-
bilities and choices, both in dialysis and transplantation,
change.
Finally, note that the prediction model presented in
this study can only be used to inform patients about
their survival chances from 90 days after their start of
RRT. The patients for whom the model can be used,
should have survived the first 90 days of RRT and the
therapy choice for their RRT therapy has been made
earlier. This prediction model is not suitable to be used
for the choice of the therapy modality at the start of the
RRT or for the acceptance or decline of a specific trans-
plant kidney offer. The therapy choice should be based on
preferences of the patient and physician, as is also the case
for the choice to accept or decline a specific transplant
kidney offer. For the choices between therapies and the
probability of death on therapies new designs are currently
emerging, based on competing risks instead of the Kaplan
Meier method [20].
Conclusions
In conclusion, with the presented prediction model it is
possible to give a reasonably accurate estimation on the
survival chances of patients who start with RRT, using a
limited set of easily available data. Future research
should establish whether it is possible to improve the
predictive performance of the prediction model using
more clinical parameters.
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